iMEDI Plus Inc.
USPTO PatentsView assignee record - 6 granted patents across 7 technology areas, recorded in grant years 2017–2019. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61B (DIAGNOSIS; SURGERY; Identification).
The verdict
According to USPTO PatentsView, imedi ranks #40,864 of 49,997 tracked US assignees by granted-patent volume, with 6 patents across 7 technology areas.
- #40,864
- of 49,997 US assignees by volume
- 21st percentile
- by Innovation Score (26.7/100)
- 17.7
- avg claims per patent
- -100%
- grant velocity, last 5 yrs
USPTO PatentsView assignee plate
Corpus R40864 · Foreign Corporation #40,864 · 6 grants
GRANTS-MICRO · LOWER-Q · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-FRNCORP · VEL-DROP · BOOK-FULL
- GRANTS-MICRO 6 grants
- LOWER-Q #40,864/49,997
- PHOTO-FINISH iBenzer
- CPC-NARROW A61B · 7 areas
- INNOV-THIN 26.7/100
- CLAIMS-RICH 17.7 claims/avg
- TYPE-FRNCORP Foreign Corp
- VEL-DROP -100% vel
- BOOK-FULL 10/10 fields
Nearest grant-volume peer: iBenzer Inc. (±0 grants)
Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.
How imedi’s 26.7 Innovation Score adds up
The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.
Innovation-score neighbourhood around imedi
Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.
- Qualcomm Incorporated · highest
Qualcomm Incorporated · highest
85 score
- iMEDI Plus · this assignee 27
iMEDI Plus · this assignee
27 score
- 3D Lighting… · lowest 7
3D Lighting… · lowest
7 score
What this shows imedi's Innovation Score is 26.7/100 (21st percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.
Does more volume mean deeper claims for imedi?
Each dot is one of imedi’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). imedi’s own 17.7 claims/patent is ABOVE the 13.0 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.
Where imedi's grants concentrate
iMEDI Plus Inc. is a focused PatentsView assignee: 7 CPC subclasses with 66.7% of grants classified under A61B (DIAGNOSIS; SURGERY; Identification). By volume, imedi sits between iBenzer Inc. and iSpot.tv, Inc..
Who files at iMEDI's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- ibenzer
iBenzer Inc.
6 patents
- icad
iCAD, Inc.
6 patents
- icell Gene Therap…
iCell Gene Therapeutics LLC
6 patents
- idonate
iDonate LLC
6 patents
- imicrodata
iMICRODATA Corporation
6 patents
- iographer
iOgrapher, LLC
6 patents
- irepertoire
iRepertoire, Inc.
6 patents
- ispot tv
iSpot.tv, Inc.
6 patents
- imedi Plus ◀
iMEDI Plus Inc.
6 patents
What this shows iMEDI holds 6 patents at rank #44,259, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Companies ranked near iMEDI
By rank, the assignees closest to #44,259 in granted patent volume.
Leaders in A61B (Diagnosis)
Other assignees with the most granted patents in iMEDI's primary technology class.
- Covidien LP 5,709 in class
- Koniniklijke Philips N.V. 3,414 in class
- Olympus Corporation 2,758 in class
- Boston Scientific Scimed, Inc. 2,362 in class
- Cilag GmbH International 2,063 in class
- Intuitive Surgical Operations, Inc. 1,921 in class
- DePuy Synthes Products, Inc. 1,796 in class
- Ethicon, Inc. 1,762 in class
imedi's Innovation Score vs. every tracked assignee
Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)
27 21st percentile higher than 21% of 49,997 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2017–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2017 | 2 | 33.3% |
| 2018 | 2 | 33.3% |
| 2019 | 2 | 33.3% |
Which technologies does iMEDI Plus Inc. patent most?
Top 7 of 7 technology areas
Data Source
USPTO PatentsView, US granted patents 2015–2025
What to do with this data
iMEDI Plus Inc.'s patent record in context - here's where to go next.
- iMEDI Plus Inc.'s lead technology class is A61B (DIAGNOSIS; SURGERY; Identification), 66.7% of its portfolio - see every assignee active in that class. Explore A61B
- Ranked #40,864 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
- Compare iMEDI Plus Inc. against iBenzer Inc., an assignee filing at a similar volume. Compare portfolios
- Innovation Score of 26.7/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated
Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.